Sigma Planning Corp Takes Position in TG Therapeutics, Inc. $TGTX

Sigma Planning Corp purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 15,375 shares of the biopharmaceutical company’s stock, valued at approximately $845,000.

A number of other large investors have also added to or reduced their stakes in TGTX. BlackRock Inc. acquired a new position in TG Therapeutics in the 2nd quarter valued at $1,211,429,000. Bank of America Corp DE acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth $71,960,000. Bank of New York Mellon Corp acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth $49,472,000. Man Group plc increased its position in shares of TG Therapeutics by 621.5% in the third quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock worth $36,431,000 after purchasing an additional 868,697 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in TG Therapeutics by 856.6% in the fourth quarter. BNP Paribas Financial Markets now owns 683,653 shares of the biopharmaceutical company’s stock valued at $20,380,000 after purchasing an additional 612,189 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of analyst reports. B. Riley Financial increased their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Jefferies Financial Group reissued a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $78.00 price objective on shares of TG Therapeutics in a research note on Tuesday. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $63.00.

TG Therapeutics Price Performance

Shares of TGTX opened at $56.09 on Wednesday. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23. The stock has a market cap of $8.59 billion, a PE ratio of 20.47, a PEG ratio of 2.33 and a beta of 1.62. TG Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $59.30. The business has a 50-day simple moving average of $53.41 and a two-hundred day simple moving average of $42.28.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The firm had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. During the same quarter last year, the firm posted $0.17 earnings per share. The business’s revenue for the quarter was up 70.2% on a year-over-year basis. Analysts anticipate that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.